Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.

Keyphrases

• Docetaxel 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Median Survival 30%
• Carboplatin 30%
• Phase II Trial 30%
• Cisplatin 30%
• Non-small Cell Lung Cancer (NSCLC) 20%
• Granulocyte Colony-stimulating Factor (G-CSF) 20%
• Phase II Study 20%
• Response Rate 20%
• Phase I Trial 20%
• Solid Tumors 10%
• Recommended Dose 10%
• Chemotherapy 10%
• Intravenous Infusion 10%
• Phase I Study 10%
• Filgrastim 10%
• Maximum Tolerated Dose 10%
• Overall Response Rate 10%
• Platinol 10%
• Time-concentration Curve 10%
• Neupogen 10%
• Tolerability 10%
• Taxotere 10%
• Platinum Compounds 10%
• Taxoids 10%
• Semi-synthetic 10%
• Previously Untreated Patients 10%
• Antitumor Activity 10%
• Nonhematologic 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Docetaxel 100%
• Cisplatin 36%
• Carboplatin 27%
• Filgrastim 18%
• Phase I Trials 18%
• Granulocyte Colony Stimulating Factor 18%
• Solid Malignant Neoplasm 9%
• Chemotherapy 9%
• Maximum Tolerated Dose 9%
• Platinum Derivative 9%
• Phase II Trials 9%
• Antitumor Activity 9%
• Tolerability 9%
• Taxoid 9%